FUJIF - FUJIFILM Holdings Corporation
| 前收市價 | 60.00 |
| 開市 | 61.36 |
| 買盤 | 無 x 無 |
| 賣出價 | 無 x 無 |
| 今日波幅 | 60.00 - 60.00 |
| 52 週波幅 | 45.26 - 61.36 |
| 成交量 | |
| 平均成交量 | 417 |
| 市值 | 24.28B |
| Beta 值 (5 年，每月) | 0.39 |
| 市盈率 (最近 12 個月) | 16.17 |
| 每股盈利 (最近 12 個月) | 3.71 |
| 業績公佈日 | 無 |
| 遠期股息及收益率 | 1.04 (1.73%) |
| 除息日 | 2023年9月28日 |
| 1 年預測目標價 | 無 |
Insider Monkey16 Largest Photography Companies In The World
In this article, we will take a look at the 16 largest photography companies in the world. If you want to see more companies in this selection, go to the 5 Largest Photography Companies in the World. According to Zion Market Research, the size of the global digital photography market stood at $105.2 billion at […]
BenzingaOnce Favored By Late Shinzo Abe, Japan Culls Development On Repurposed COVID-19 Treatment
Fujifilm Holdings Corp (OTC: FUJIY) (OTC: FUJIF) has discontinued the development of its anti-influenza drug, Avigan (favipiravir), for use as a therapeutic drug against COVID-19. In 2021, Fujifilm Toyama Chemical began a phase 3 clinical trial in Japan with a target enrollment of 316 subjects to confirm Avigan's efficacy in preventing the progression to severe symptoms in COVID-19 patients who have not yet been vaccinated. However, enrollment was terminated at 84 subjects in March 2022 followin